Novel personalized medicine technology: UGT1A1 testing for irinotecan as a case study

Personalized Medicine

Volumn 3, Issue 4, 2006, Pages 415-419

  Van Bebber, Stephanie L ^a   Keegan, Hugh L ^b,c   Phillips, Kathryn A ^a   Issa, Amalia M ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

Author keywords

Camptosar ; Clinical and policy implications; Database; Diffusion of innovations; Irinotecan; Personalized medicine; UGT1A1 testing

Indexed keywords

FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; OXALIPLATIN;

ARTICLE; CLINICAL PRACTICE; COLORECTAL CANCER; DIAGNOSTIC TEST; DIARRHEA; DOSE CALCULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG LABELING; DRUG MARKETING; DRUG SAFETY; ETHNIC DIFFERENCE; EVIDENCE BASED PRACTICE; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE UTILIZATION; HUMAN; LOW DRUG DOSE; MEDICAL TECHNOLOGY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT EDUCATION; PATIENT MONITORING; PHARMACOGENOMICS; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT PLANNING; VALIDATION PROCESS;

EID: 33845863919     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.3.4.415     Document Type: Article

References (23)

1. Andersson T, Flockhart DA, Goldstein DB et al.: Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther. 78(6), 559-581 (2005).
2. Sadee W, Dai Z: Pharmacogenetics/genomics and personalized medicine. Human Mol. Genet. 14(1), R207-R214 (2005).
3. American Cancer Society: Colorectal Cancer Facts & Figures Special Edition. American Cancer Society, Atlanta, GA, USA (2005).
4. Goldberg RM: Advances in the treatment of metastatic colorectal cancer. Oncologist 10(Suppl. 3), 40-48 (2005).
5. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDP-glucuronasyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22(8), 1382-1388 (2004).
6. Fuchs CS, Moore MR, Harker G et al.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol. 21, 807-814 (2003).
7. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N. Engl. J. Med. 345, 144-146 (2001).
8. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J. Clin. Oncol. 19, 3801-3807 (2001).
9. Marcuello E, Altes A, Menoyo A et al.: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91(4), 678-682 (2004).
10. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-glucuronosyltransferasegene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60, 6921-6926 (2000).
11. Massacesi C, Terrazzino S, Marcucci F et al.: Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106(5), 1007-1016 (2006).
12. Rouits E, Boisdron-Celle M, Dumont A et al.: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Can. Res. 10, 5151-5159 (2004).
13. Guillemette C: Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3(3), 136-158 (2003).
14. Hasegawa Y, Ando Y, Shimokata K: Screening for adverse reactions to irinotecan treatment using the Invader® UGT1A1 Molecular Assay. Expert Rev. Mol. Diagn. 6(4), 527-533 (2006).
15. Hasegawa Y, Sarashina T, Ando M et al.: Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin. Chem. 50(8), 1479-1480 (2004).
16. Innocenti F, Vokes EE, Ratain MJ: Irinogenetics: what Is the right star? J. Clin. Oncol. 24(15), 2221-2224 (2006).
17. McLeod HL, Watters JW: Irinotecan pharmacogenetics: is it time to intervene? J. Clin. Oncol. 22(8), 1356-1359 (2004).
18. Phillips KA, Van Bebber SL, Issa AM: Initial development of an evidence base for personalized medicine's translation to clinical practice and health policy. Personalized Medicine 3(4), 417-420 (2006).
19. Davis RL, Khoury MJ: A public health approach to pharmacogenomics and gene-based diagnostic tests. Pharmacogenomics 7(3), 331-337 (2006).
20. Phillips KA, Van Bebber SL: Measuring the value of pharmacogenomics. Nat. Rev. Drug Discov. 4(6), 500-509 (2005).
21. Phillips KA, Van Bebber SL: Cost-effectiveness of pharmacogenomic interventions: a systematic review of the literature. Pharmacogenomics 5(8), 1139-1149 (2004).
22. Bosma PJ, Chowdhury JR, Bakker CTM et al.: The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333, 1171-1175 (1995).
23. Yong WP, Ramirez J, Innocenti F, Ratain MJ: Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin. Cancer Res. 11(18), 6699-6704 (2005).